相关实验视频

Updated: Jul 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

在HER2-阳性转移性乳腺癌中治疗方法和结果的发展:来自GIM14/BIOMETA研究的数据

Massimo Di Maio1, Claudia Bighin2, Francesco Schettini3

  • 1Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy.

Breast (Edinburgh, Scotland)
|October 2, 2023
PubMed
概括

自2014年以来,对HER2阳性转移性乳腺癌的第一线治疗得到了改善,无进展生存期 (PFS) 较长,主要是由于pertuzumab. 肝转移患者的结果也得到改善,但脑转移仍然是一个挑战.

关键词:
乳腺癌 乳腺癌 乳腺癌治疗的第一线治疗.她是HER2阳性的.转移 转移 转移 转移这就是Trastuzumab.

更多相关视频

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K